scispace - formally typeset
A

Andreas Strasser

Researcher at Walter and Eliza Hall Institute of Medical Research

Publications -  537
Citations -  75592

Andreas Strasser is an academic researcher from Walter and Eliza Hall Institute of Medical Research. The author has contributed to research in topics: Apoptosis & Programmed cell death. The author has an hindex of 128, co-authored 509 publications receiving 66903 citations. Previous affiliations of Andreas Strasser include University of Alabama at Birmingham & Basel Institute for Immunology.

Papers
More filters
Journal ArticleDOI

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

TL;DR: In this paper, the authors reveal the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconcile the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia.
Journal ArticleDOI

Combined loss of proapoptotic genes Bak or Bax with Bim synergizes to cause defects in hematopoiesis and in thymocyte apoptosis

TL;DR: Thymocytes isolated from Bak+/−Bim−/− or Bax/Bim +/− mice are markedly more resistant to apoptotic stimuli mediated by the intrinsic pathway as compared with thymocytes from single-knockout mice, suggesting an essential overlapping role for Bak or Bx and Bim in the intrinsic apoptotic pathway.
Journal ArticleDOI

Discovery and molecular characterization of a Bcl-2–regulated cell death pathway in schistosomes

TL;DR: The identification and characterization of a Bcl-2–regulated apoptosis pathway in Schistosoma japonicum and S. mansoni is described and it is shown that a schistosome prosurvival protein, sjA, binds ABT-737, a well-characterized BH3 mimetic.
Journal ArticleDOI

BCL-2: Long and winding path from discovery to therapeutic target.

TL;DR: The long and winding path from the discovery of this protein and understanding the fundamental process of apoptosis that BCL-2 and its numerous homologues control, through to its exploitation as a drug target that is set to have significant benefit for cancer patients is described.